<DOC>
	<DOCNO>NCT00450424</DOCNO>
	<brief_summary>RATIONALE : The use CD-ROM may help patient colorectal cancer family history colorectal cancer make inform decision undergo microsatellite instability ( MSI ) test . PURPOSE : This randomized clinical trial study educational CD-ROM see well work compare standard inform consent assist decision-making MSI test patient colorectal cancer family history colorectal cancer .</brief_summary>
	<brief_title>Educational CD-ROM Compared With Standard Informed Consent Patients With Colorectal Cancer Family History Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare impact standard inform consent v CD-ROM educational intervention knowledge microsatellite instability ( MSI ) test patient colorectal cancer ( CRC ) family history CRC . - Determine impact intervention patient satisfaction preparation make decision . Secondary - Determine whether CD-ROM educational intervention differential impact satisfaction MSI test decision , difficulty make MSI test decision , decisional conflict , well patient ' attitude MSI test CRC ( e.g. , perceive benefit barrier MSI test , perceive risk colorectal related cancer , self-efficacy ) , general cancer-related distress , discussion family member MSI test familial CRC risk . - Assess whether demographic factor , disease/family history characteristic , family support test , cancer-related distress moderate impact intervention satisfaction completeness inform consent process . OUTLINE : This multicenter , pilot , study ( part I ) follow randomize study ( part II ) . - Part I : The educational CD-ROM develop 9 month . Patients receive pilot version CD-ROM provide feedback regard usability content . - Part II : Patients randomize 1 2 arm . - Arm I : Patients complete baseline interview receive standard inform consent microsatellite instability ( MSI ) test brief , standardize explanation MSI test . - Arm II : Patients complete baseline interview receive standard inform consent MSI test educational CD-ROM develop phase I . All patient part II ( even consent MSI test ) complete follow-up survey 2 week . Tissue sample patient analyzed immunohistochemistry MSI assay ( polymerase chain reaction ) MLH1 MSH2 . PROJECTED ACCRUAL : A total 184 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms , Hereditary Nonpolyposis</mesh_term>
	<criteria>Patient family member meeting 1 follow revise Bethesda colorectal cancer ( CRC ) criterion : Diagnosis colon rectal cancer &lt; 50 year age Diagnosis &gt; 1 CRC one time past Diagnosis ≥ 1 CRC different time Diagnosis CRC hereditary nonpolyposis colorectal cancer ( HNPCC ) relate cancer Diagnosis CRC ≥ 2 firstdegree seconddegree relative HNPCCrelated tumor ≥ 1 cancer diagnose &lt; 50 year age Diagnosis CRC ≥ 2 first seconddegree relative HNPCCrelated tumor , regardless age Diagnosis CRC pathologic feature suggestive microsatellite instability ( MSI ) &lt; 60 year age Patients CRC meeting Amsterdam criterion define ineligible : Three relative CRC 1 firstdegree relative 2 Cases span ≥ 2 generation At least 1 CRC case diagnose 50 year age PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>hereditary non-polyposis colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage IIA colon cancer</keyword>
	<keyword>stage IIB colon cancer</keyword>
	<keyword>stage IIIA colon cancer</keyword>
	<keyword>stage IIIB colon cancer</keyword>
	<keyword>stage IIIC colon cancer</keyword>
	<keyword>stage IVA colon cancer</keyword>
	<keyword>stage IVB colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage IIA rectal cancer</keyword>
	<keyword>stage IIB rectal cancer</keyword>
	<keyword>stage IIC rectal cancer</keyword>
	<keyword>stage IIIA rectal cancer</keyword>
	<keyword>stage IIIB rectal cancer</keyword>
	<keyword>stage IIIC rectal cancer</keyword>
	<keyword>stage IVA rectal cancer</keyword>
	<keyword>stage IVB rectal cancer</keyword>
</DOC>